Determinants of Paucibacillary Mtb Infection in Mice

NIH RePORTER · NIH · U19 · $572,472 · view on reporter.nih.gov ↗

Abstract

Tuberculosis (TB) chemotherapy eliminates disease symptoms, but often fails to sterilize Mycobacterium tuberculosis (Mtb) leaving apparently cured TB patients at risk of disease relapse. How Mtb survives during post- treatment persistent infections (PTPI) is ill defined and we lack a full understanding of the immune determinants that prevent progression to active TB (relapse). We developed a paucibacillary (low bacterial numbers) mouse model that mimics PTPI in in humans. We found that silencing of in vivo essential genes cured Mtb infections in mice to the extent that colony forming units (CFU) were no longer detected on agar plates. However, as in humans, mice were often not sterilized, and paucibacillary infection resulted in relapse TB. Our model allows us to interrogate both, the mechanisms that enable Mtb to persist despite host immunity and the host factors that are required to control and sterilize Mtb infection. We will use this model to (1) compare post-treatment persistent infection (PTPI) in mice and humans (2) determine the importance of specific leukocyte subsets for the establishment or control of paucibacillary Mtb infection and (3) identify Mtb genes that are required for paucibacillary persistence.

Key facts

NIH application ID
10430228
Project number
5U19AI162568-02
Recipient
WEILL MEDICAL COLL OF CORNELL UNIV
Principal Investigator
SABINE EHRT
Activity code
U19
Funding institute
NIH
Fiscal year
2022
Award amount
$572,472
Award type
5
Project period
2021-07-01 → 2026-04-30